Hyphens Pharma's Q3 Net Profit Falls to $2m
Hyphens Pharma's Q3 Net Profit Falls to $2m
Revenue rose 2.5% year-on-year from $42.8m to $43.9m, driven by stronger sales in Singapore and Malaysia. Meanwhile, revenue rose thanks to stronger sales in Singapore and Malaysia.
同时，由于新加坡和马来西亚的销售强劲，收入增长。
Hyphens Pharma International Limited's net profit for the third quarter fell by 5.6% to $2m, down from $2.1m in the same period last year, its bourse filing showed.
Hyphens Pharma International Limited的证券交易所文件显示，其第三季度的净利润从去年同期的210万美元下降了5.6％，至200万美元。
The group attributed the decline to higher distribution and manpower costs and increased administrative expenses. This was partially offset by a higher gross profit and exchange gains from favourable currency movements against the US dollar and euro.
该集团将下降归因于分配和人力成本的增加以及管理开支的增加。由于货币兑美元和欧元的有利波动，毛利润和汇兑收益的增加部分抵消了这一点。
Revenue rose 2.5% year-on-year from $42.8m to $43.9m, driven by stronger sales in Singapore and Malaysia.
受新加坡和马来西亚销售强劲的推动，收入同比增长2.5％，从4,280万美元增至4,390万美元。
September revenue increased by 22.1% to $143.5m, mainly due to growth in the specialty pharma principals segment, including new sales from distributorships with Laboratoires Gilbert S.A.S and higher demand for its medical aesthetics range.
9月份收入增长了22.1％，达到1.435亿美元，这主要是由于特种药品主要业务板块的增长，包括与Laboratoires Gilbert S.A.S的分销业务的新销售额以及对其医学美容系列的需求增加。
Revenue from the proprietary brands segment grew by 16.9%, whilst the medical hypermart and digital segments posted a 3% increase.
专有品牌板块的收入增长了16.9％，而医疗超市和数字板块的收入增长了3％。
